Join Growin Stock Community!

Clearside biomedical, inc.CLSD.US Overview

US StockHealthcare
(No presentation for CLSD)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CLSD AI Insights

CLSD Overall Performance

CLSD AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CLSD Recent Performance

-

Clearside biomedical, inc.

3.18%

Avg of Sector

-0.48%

S&P500

CLSD PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CLSD Key Information

CLSD Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CLSD Profile

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Price of CLSD

CLSD FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CLSD Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.97
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-29.74%
Net Margin
-8495.42%
Revenue Growth (YoY)
-96.03%
Profit Growth (YoY)
-101.18%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.97
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
-29.74%
Net Margin
-8495.42%
Revenue Growth (YoY)
-96.03%
Profit Growth (YoY)
-101.18%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is CLSD's latest earnings report released?

    The most recent financial report for Clearside biomedical, inc. (CLSD) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CLSD's short-term business performance and financial health. For the latest updates on CLSD's earnings releases, visit this page regularly.

  • How is CLSD's revenue growth?

    In the latest financial report, Clearside biomedical, inc. (CLSD) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does CLSD have?

    As of the end of the reporting period, Clearside biomedical, inc. (CLSD) had total debt of 61.61M, with a debt ratio of 5.29. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CLSD have?

    At the end of the period, Clearside biomedical, inc. (CLSD) held Total Cash and Cash Equivalents of 6.8M, accounting for 0.58 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is CLSD's EPS continuing to grow?

    According to the past four quarterly reports, Clearside biomedical, inc. (CLSD)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.14. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CLSD?

    Clearside biomedical, inc. (CLSD)'s Free Cash Flow (FCF) for the period is -5.48M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 8.15% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.